Global Blood Therapeutics Inc (GBT) : Casdin Capital scooped up 325,000 additional shares in Global Blood Therapeutics Inc during the most recent quarter end , the firm said in a disclosure report filed with the SEC on Aug 15, 2016. The investment management firm now holds a total of 430,000 shares of Global Blood Therapeutics Inc which is valued at $9,438,500.Global Blood Therapeutics Inc makes up approximately 8.28% of Casdin Capital’s portfolio.
Other Hedge Funds, Including , Cubist Systematic Strategies added GBT to its portfolio by purchasing 5,665 company shares during the most recent quarter which is valued at $124,347. Global Blood Therapeutics Inc makes up approx 0.01% of Cubist Systematic Strategies’s portfolio. Laurion Capital Management Lp added GBT to its portfolio by purchasing 105,000 company shares during the most recent quarter which is valued at $2,304,750. Global Blood Therapeutics Inc makes up approx 0.14% of Laurion Capital Management Lp’s portfolio.Janus Capital Management boosted its stake in GBT in the latest quarter, The investment management firm added 471,229 additional shares and now holds a total of 1,249,686 shares of Global Blood Therapeutics Inc which is valued at $27,430,608. Global Blood Therapeutics Inc makes up approx 0.02% of Janus Capital Management’s portfolio.Geode Capital Management boosted its stake in GBT in the latest quarter, The investment management firm added 9,282 additional shares and now holds a total of 62,715 shares of Global Blood Therapeutics Inc which is valued at $1,376,594. Tfs Capital sold out all of its stake in GBT during the most recent quarter. The investment firm sold 40,343 shares of GBT which is valued $885,529.
On the company’s financial health, Global Blood Therapeutics Inc reported $-0.58 EPS for the quarter, beating the analyst consensus estimate by $ 0.05 according to the earnings call on Aug 10, 2016. Analyst had a consensus of $-0.63.During the same quarter in the previous year, the company posted $-4.84 EPS.
Global Blood Therapeutics Inc. is a biopharmaceutical company that engages in discovering developing and commercializing therapeutics to treat blood-based disorders. The Company is engaged in developing initial product candidate GBT440 oral prophylactic therapy for sickle cell disease (SCD). The Company offers randomized placebo-controlled double-blind single and multiple ascending dose Phase 1/2 clinical trial of GBT440 in healthy subjects and patients with SCD. It is also developing hemoglobin modifiers for pulmonary disorders such as acute respiratory distress syndrome in which increased oxygen delivery is needed. The Company through its GBT440 or analog also focuses on chemical and biological mechanisms of blood-based disorders to target hypoxemic pulmonary disorders and hereditary angioedema (HAE) which is in pre-clinical trials. In addition the Company develops TBD an oral kallikrein inhibitor which are in Phase 1/2 clinical trials.